Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Transplantation Proceedings|September 5, 2018
Pericarditis in Patients With Chronic Graft-vs-Host DiseaseE Karakulska-Prystupiuk, G Basak, J Dwilewicz-Trojaczek, et al.
The International Journal of Biochemistry & Cell Biology|November 21, 2000
Lovastatin and simvastatin are modulators of the proteasomeC Wójcik, M Bury, T Stoklosa, et al.
Bone Marrow Transplantation|August 20, 2013
Uptake and use of recommendations for the diagnosis, severity scoring and management of chronic GVHD: an international survey of the EBMT-NCI Chronic GVHD Task ForceR F Duarte, H Greinix, B Rabin, et al.
Pediatric Hematology and Oncology|October 22, 2019
Management of growth failure and growth hormone deficiency after pediatric allogeneic HSCT: Endocrinologists are of importance for further guidelines and studiesA Lawitschka, P Schwarze, A Rovelli, et al.
Cancer Letters|February 17, 2001
Antitumor activity of tributyrin in murine melanoma modelA Giermasz, D Nowis, A Jalili, et al.
Transplantation Proceedings|September 5, 2018
Azacitidine for Relapse After Allogeneic Stem Cell Transplantation-Single-Center StudyE Karakulska-Prystupiuk, J Drozd-Sokołowska, A Waszczuk-Gajda, et al.
Bone Marrow Transplantation|November 29, 2016
The EBMT-ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysisT Ruutu, A Gratwohl, D Niederwieser, et al.
Bone Marrow Transplantation|July 18, 2021
Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults: an EBMT cross-sectional non-interventional studyD M Greenfield, N Salooja, C Peczynski, et al.
Bone Marrow Transplantation|November 25, 2023
Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP studyA Mussetti, B Rius-Sansalvador, V Moreno, et al.
Pageof 1